JAGX · Jaguar Health, Inc.
$0.79
-0.02 (-2.32%)
At close · Aug 31
Going-concern doubt
— flagged Aug 19, 2026
Substantial doubt about the company's ability to continue as a going concern.
“While management believes this infusion improves our liquidity, it does not fully alleviate the conditions that raise substantial doubt about our ability to continue as a going concern for one year from the issuance of these financial statements.”View the 10-Q filed Aug 19, 2026
Market Cap
$4.19M
Shares
5.17M
Jaguar Health, Inc. Earnings Call Transcripts
Quarterly earnings calls for Jaguar Health, Inc. (JAGX), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$2.81M
−$7.78M
'23 Q3
23-09-30
·
$2.35M
−$9.23M
'24 Q1
24-03-31
·
$2.72M
−$9.49M
'24 Q2
24-08-13
▲10.5%
$3.11M
−$9.85M
'24 Q3
24-11-13
·
$3.51M
−$9.92M
'24 Q4
25-03-31
▼5.8%
$2.21M
−$10.46M
'25 Q1
25-05-15
▲9.5%
$2.98M
−$10.41M
'25 Q2
25-06-30
▲815.6%
$20.27M
$8.72M
'26 Q1
26-05-26
LATEST
▼58.9%
$1.23M
−$12.80M
'26 Q2
26-08-19
Earnings call
FY26 · Q2
2026-08-19
Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Transcript
Confident tone
Near-term clinical and regulatory catalysts
FuturePac out-license of Mytesi/Canalevia
Prescription product revenue decline
Revenue
$1.23M
▼ 58.9% YoY Diluted EPS
$-15.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY26 · Q1
2026-05-26
Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Transcript
Confident tone
Rare disease intestinal failure program
Crofe/crofellamer pipeline focus
FuturePAC out-license deal
Revenue
$20.27M
▲ 815.6% YoY Diluted EPS
$-13.60
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Jaguar Health, Inc. (JAGX) Q2 2025 Earnings Call Transcript
Confident tone
Clinical catalysts in MVID/SBS
Animal Health / Canalevia partnership
Oncology label expansion (CTD/metastatic breast cancer)
Revenue
$2.98M
▲ 9.5% YoY Diluted EPS
$-358.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-15
Jaguar Health, Inc. (JAGX) Q1 2025 Earnings Call Transcript
Positive tone
Rare disease program (MVID / SBS-IF)
Crofelemer / Mytesi prescription sales
Business development and partnerships
Revenue
$2.21M
▼ 5.8% YoY Diluted EPS
$-584.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Jaguar Health, Inc. (JAGX) Q4 2024 Earnings Call
Revenue
$3.51M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-13
Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript
Confident tone
Crofelemer pipeline and orphan indications
FDA engagement and regulatory pathway
OnTarget Phase III trial results and breast cancer subgroup
Revenue
$3.11M
▲ 10.5% YoY Diluted EPS
$-920.15
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-13
Jaguar Health, Inc. (JAGX) Q2 2024 Earnings Call Transcript
Positive tone
Crofelemer clinical pipeline
Rare/orphan disease indications (MVID/SBS)
Gelclair commercial launch
Revenue
$2.72M
Diluted EPS
$-93.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Jaguar Health, Inc. (JAGX) Q1 2024 Earnings Call Transcript
Positive tone
Pipeline and business focus
Gelclair / oral mucositis expansion
Financial losses / operating loss
Revenue
$2.35M
Diluted EPS
$-3049.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Jaguar Health, Inc. (JAGX) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Jaguar Health, Inc. (JAGX) Q3 2023 Earnings Call Transcript
Revenue
$2.81M
Diluted EPS
$-19687.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-14
Jaguar Health, Inc. (JAGX) Q2 2023 Earnings Call Transcript
Diluted EPS
$-36181.25
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-15
Jaguar Health, Inc. (JAGX) Q1 2023 Earnings Call Transcript
Diluted EPS
$-125475.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-27
Jaguar Health, Inc. (JAGX) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-14
Jaguar Health, Inc. (JAGX) Q3 2022 Earnings Call Transcript
Diluted EPS
$-463575.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-06-30
Jaguar Health, Inc. (JAGX) Q2 2022 Earnings Call Transcript
Diluted EPS
$-460425.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Jaguar Health, Inc. (JAGX) Q1 2022 Earnings Call Transcript
Diluted EPS
$-1212750.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-11
Jaguar Health, Inc. (JAGX) Q4 2021 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-18
Jaguar Health, Inc. (JAGX) Q3 2021 Earnings Call
Diluted EPS
$-1063125.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-17
Jaguar Health, Inc. (JAGX) Q1 2021 Earnings Call
Diluted EPS
$-1102500.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q3
2020-11-16
Jaguar Health, Inc. (JAGX) Q3 2020 Earnings Call Transcript
Revenue
$2.77M
▲ 185% YoY Diluted EPS
$-2441250.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-13
Jaguar Health, Inc. (JAGX) Q2 2020 Earnings Call Transcript
Revenue
$3.17M
▲ 85.6% YoY Diluted EPS
$-5197500.00
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-04-06
Jaguar Health, Inc. (JAGX) Q1 2020 Earnings Call Transcript
Revenue
$869,000
▼ 45.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–22 of 22 earnings calls